«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2020年03期

页码:

307-313

栏目:

论著

出版日期:

2020-06-20

文章信息/Info

Title:

Effect of curcumine on migration and invasion of A549 cells

作者:

畅 婕¹; 高宏祥¹; 杨拴盈²; 杜建飞¹

710016 西安,长安医院肿瘤科¹ 710004 西安,西安交通大学第二附属医院呼吸科²

Author(s):

Tan Dan¹;  Zeng Xiaoqin²;  Xu Wei¹;  Chen Jian³;  Zhou Renjie¹.

¹Emergency and General Medical Center, ²Department of Respiratory and Critical Care Medicine, and ³ Military Institute of Immunology, Second Affiliated Hospital, Army Military Medical University, Chongqing 400037, China

关键词:

阿帕替尼;  小细胞肺癌;  血管内皮生长因子

Keywords:

Curcumine;  Bronchogenic carcinoma;  A549 cells;  Migration;  Invasion;  EMT

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2020.03.004

摘要:

目的 探讨姜黄素对肺癌A549细胞侵袭迁移力的影响及其机制。方法 利用不同浓度姜黄素处理正常肺上皮细胞,台盼蓝法检测药物细胞毒性; 不同浓度的姜黄素作用于A549细胞,MTT法测定A549细胞增殖水平; 细胞划痕实验和Transwell实验分别测定药物处理后A549细胞的迁移和侵袭能力变化情况; Werstern blot测定A549细胞中于侵袭迁移有关的表皮生长因子受本(EGFR)、E-型钙黏蛋白(E-cadherin)、N-型钙黏蛋白(N-cadherin)蛋白的表达。结果 姜黄素浓度在0～40 μg/ml时正常肺上皮病死率低,差异无明显统计学差异(P>0.05),表明姜黄素对正常肺上皮细胞的不良反应小; MTT实验结果显示姜黄素以浓度依赖的方式抑制A549细胞的增殖,各组与对照组相比均具有统计学意义(P<0.01); 细胞划痕实验显示姜黄素以浓度依赖的方式抑制A549细胞的迁移能力,各组与对照组相比均具有统计学意义(P<0.01); Transwell实验显示姜黄素以浓度依赖的方式抑制A549细胞的侵袭能力,各组与对照组相比均具有统计学意义(P<0.01); Western blot显示姜黄素处理A549细胞后EGFR蛋白(P<0.01)和N-cadherin蛋白表达降低(P<0.01),E-cadherin蛋白表达升高(P<0.01)。结论 一定浓度内姜黄素细胞毒性低,姜黄素能够抑制A549的增殖、迁移和侵袭,可能是通过调节EGFR、N-cadherin、E-cadherin蛋白从而逆转上皮间质转化过程。

Abstract:

Objective To explore the effect and mechanism of curcumine on the migration and invasion of A549 cells. Methods Trypan blue dye exclusion assay was used to determine the effect of various concentrations of curcumine on the cell death rate. The proliferation of A549 cells was detected by MTT assay. The migration and invasion of A549 cells were determined by wound scratch assay and Transwell assay, respectively. The expression levels of EGFR, E-cadherin and N-cadherin in A549 cells affected by curcumine were detected by Western blotting method. Results When the curcumine concentration was 0-40 μg/ml, the mortality rate of the normal lung epithelial cells was low, and the difference was not statistically significant(P>0.05), indicating that curcumine had little toxic and side effects on the normal lung epithelial cells. The MTT results showed that curcumine inhibited the proliferation of A549 cells in a concentration-dependent manner, compared with the control group, and statistical significant difference was found between the two groups(P<0.01). The cell scratch experiment showed that the migration ability of A549 cells was reduced after treatment of curcumine for 24 hours, compared with the control group, and statistical significant difference was found between the two groups(P<0.01). Transwell assay showed that the invasiveness of A549 cells was decreased with the least amount of curcumine, compared with the control group, and statistical significant difference was found between the two groups(P<0.01). Western blotting showed that the expression of epidermal growth factor receptor(EGFR, P<0.01)and N-cadherin protein were decreased(P<0.01)and the expression of E-cadherin protein was increased(P<0.01)after treatment of 40 μg/ml of curcumine on A549 cells, compared with the control group, and statistical significant difference was found between the two groups. Conclusion Curcumine can inhibit the proliferation, migration and invasion of A549 cells probably through down-regulating the expression of EGFR and N-cadherin and regulating the expression of E-cadherin, and therefore reversing the process of epithelial stromal transformation.

参考文献/References:

1 钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
2 李王平, 马李杰, 潘 蕾, 等. 白藜芦醇对小细胞肺癌C-myc基因表达的调控研究[J/CD]. 中华肺部疾病杂志(电子版), 2020, 13(2): 148-153.
3 Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer(SCLC): no treatment advances in recent years[J]. Translat Lung Cancer Res, 2016, 5(1): 39-50.
4 Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454.
5 Zhang L, Shi M, Huang C, et al. A phase Ⅱ, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer(NSCLC)after two previous treatment regimens[J]. J Clin Oncol, 2012, 30(15suppl): 1123-1134.
6 Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. Bmc Cancer, 2014, 14(1): 820-826.
7 刘 斌, 秦建文, 周静敏. 复发性小细胞肺癌治疗进展[J].中国肺癌杂志, 2017, 20(3): 192-198.
8 Tartarone A, Giordano P, Lerose R, et al. Progress and challenges in the treatment of small cell lung cancer[J]. Med Oncol, 2017, 34(6): 110.
9 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
10 Dowell JE, Amirkhan RH, Lai WS, et al. Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2.[J]. Anticancer Res, 2004, 24(4): 2367-2373.
11 袁晓晗, 杨 杰, 秦婷婷, 等. VEGFA和VEGFR2对肺腺癌患者术后无病生存的预测价值[J]. 肿瘤, 2017, 37(7): 716-722.
12 Horn L, Dahlberg SE, Sandler AB, et al. Phase Ⅱ study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.[J]. J Clin Oncol Oncol, 2011, 27(35): 6006-6011.
13 Spigel DR, Townley PM, Waterhouse DM, et al. Randomized Phase Ⅱ Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial[J]. J Clin Oncol, 2011, 29(16): 2215-2222.
14 Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase Ⅱ Study[J]. J Clin Oncol, 2011, 29(33): 4436-4441.
15 Pujol JL, Lavole A, Quoix E, et al. Randomized phase Ⅱ-Ⅲ study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial.[J]. Ann Oncol, 2015, 26(5): 908-914.
16 Tiseo M, Boni L, Ambrosio F, et al. 3*Italian multicenter phase Ⅲ randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer(SCLC): GOIRC-AIFA FARM6PMFJM trial[J]. J Clin Oncol, 2017, 35(12): 1281-1287.
17 Jalal S, Bedano P, Einhorn L, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.[J]. J Thorac Oncol, 2010, 5(12): 2008-2011.
18 Geng R, Li J. Apatinib for the treatment of gastric cancer[J]. Expert Opin Pharmacother, 2015, 16(1): 117-122.
19 Lin Y, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J]. Oncotarget, 2017, 8(26): 42252-42261.
20 Hong W, Li H, Jin XY, et al. P1.07-053 Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study.[J]. J Thorac Oncol, 2017, 12: S729.
21 曲范杰, 于韦韦, 张 捷. 阿帕替尼联合化疗治疗晚期小细胞肺癌1例报告及文献复习[J]. 中国肿瘤生物治疗杂志, 2017, 11(8): 923-925.
22 秦叔逵, 李 进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015, 20(9): 841-847.
23 Fengying W, Shijia Z, Anwen X, et al. A phase Ⅱ clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2018, 19(6): e831-e842.
24 Xue J, Astère M, Zhong M, et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis[J]. Onco Targets Ther, 2018, 11: 6119-6128.
25 王晓蕊, 汪 旭, 史业辉, 等. 阿帕替尼治疗晚期难治性三阴性乳腺癌的临床疗效观察[J]. 中国肿瘤临床, 2017, 11(15): 769-772.
26 孙培培, 张 龙, 张 泰, 等. 单药阿帕替尼治疗二线及二线以上化疗失败的晚期大肠癌患者疗效分析[J]. 临床肿瘤学杂志, 2017, 22(7): 646-649.
27 Petereit C, Zaba O, Teber I, et al. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan[J]. Bmc Pulm Med, 2013, 13(1): 55-55.
28 Onitilo AA, Kio E, Doi SA. Tumor-related hyponatremia[J]. Clin Med Res, 2007, 5(4): 228-237.
29 Zhang Y, Jing YU, Oncology DO, et al. Study on the efficacy and safety of Apatinib in treatment of advanced malignant tumor[J]. J Clin Experiment Med, 2018, 9: 20-24.
30 Van Heeckren WJ, Ortiz J, Coonky MM, et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?[J]. J Clin Oncol, 2007, 25(21): 2993-2995.
31 Lankhorst S, Kappers MH, van Esch JH, et al. Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress[J]. Antioxidants Redox Signal, 2014, 20(1): 135-145.
32 赵青芳, 关露露, 吕慧芳, 等. 阿帕替尼治疗晚期胃癌的疗效预测和预后分析[J]. 中国癌症杂志, 2018, 28(3): 203-209.

备注/Memo

备注/Memo:

基金项目: 国家自然科学基金资助项目(81672300)

常用功能

更新日期/Last Update: 2020-06-20